The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Alkermes stock can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is Alkermes Stock A Buy?
Alkermes stock is working on a flat base with a 29.59 entry. See if the stock can break out in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Although earnings and sales growth came in at -39% and -6%, respectively, in the latest report, that showed improvement for both the top and bottom lines. The biotech company is expected to release its next quarterly numbers on or around Apr. 27.
Alkermes stock holds the No. 135 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
